TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 1678.
Locate Jan Aushadhi KendraClinical Overview
Coenzyme Q10 / Ubidecarenone Capsules (60mg, 100mg, 300mg; alone or with L-Carnitine, Lycopene, Zinc) is an essential mitochondrial electron transport cofactor and fat-soluble antioxidant on the PMBI Formulary. It functions in the inner mitochondrial membrane to facilitate electron transfer from complexes I/II to complex III for ATP generation, while scavenging free radicals in lipid membranes. Replenishes CoQ10 depletion caused by HMG-CoA reductase inhibitors (statins). Indicated for adjuvant support in congestive heart failure, statin-induced myopathy, male subfertility (sperm motility enhancement), and neurodegenerative conditions.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 100 mg to 300 mg daily with a meal containing dietary fat with water. CoQ10 is lipophilic; absorption is enhanced 3-fold when taken with fatty foods.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Extremely well tolerated. Common: Mild dyspepsia, nausea, diarrhea, insomnia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Over-The-Counter nutritional supplement. Structurally related to vitamin K; may modestly decrease anticoagulant response to warfarin (monitor INR).
Medical Disclaimer: Statutory Nutritional & Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or clinical dietetic guidance. Dietary supplements, micronutrients, parenteral electrolytes, and specialized clinical nutrition should be used under the supervision of a registered medical practitioner or clinical nutritionist.
Calcium 500mg and Vitamin D3 250IU Tablets
Cholecalciferol (Vitamin D3 Drops 400 IU/ml, 800 IU/ml) is a physiological pediatric liquid formulation on the WHO Model List of Essential Medicines. Promotes normal bone growth and dentition in infants and children. Indicated for prevention of nutritional rickets and maintenance of healthy skeletal development in breastfed infants.
Vitamin B-Complex fort Zinc Capsule
Vitamin B-Complex Formulations (Tablets, Capsules with Zinc, Syrup, and Injection) is a balanced formulation of essential B-group vitamins (B1 Thiamine, B2 Riboflavin, B3 Niacinamide, B5 Calcium Pantothenate, B6 Pyridoxine, B9 Folic Acid, B12 Cobalamin) on the WHO Model List of Essential Medicines. B-vitamins act as critical water-soluble coenzymes in cellular Krebs cycle energy production, carbohydrate and lipid metabolism, erythropoiesis, and myelin integrity. Indicated for prevention and treatment of generalized B-complex deficiencies, aphthous stomatitis/glossitis/angular cheilitis, convalescence, chronic debilitating illness, and nutritional maintenance during prolonged antibiotic therapy.
Vitamin B-Complex Tablets (B1, B2, B3, B5, B6, B12)
Thiamine Hydrochloride Tablets (100mg) is an oral Vitamin B1 preparation on the WHO Model List of Essential Medicines for prevention and treatment of thiamine deficiency, dry and wet beriberi, and nutritional support in chronic alcoholism.
Calcium Carbonate 500mg, Calcitriol 0.25mcg and Zinc 7.5mg Capsules
Calcitriol Capsules (0.25mcg; alone or in bone complexes with Calcium, Vitamin K2-7, Zinc) is the biologically active hormonal form of vitamin D3 (1,25-dihydroxycholecalciferol) on the WHO Model List of Essential Medicines. Unlike cholecalciferol, it requires no metabolic activation by the liver or kidneys, directly activating intestinal calcium absorption and bone remodeling. Indicated for management of hypocalcemia and renal osteodystrophy in patients with chronic kidney disease, hypoparathyroidism, pseudohypoparathyroidism, and severe osteoporosis.